Treatment of relapsed or refractory chronic lymphocytic leukemia. - Wikidata - wikimedia - TriplyDB

Treatment of relapsed or refractory chronic lymphocytic leukemia.

Treatment of relapsed or refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37964916

about

Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Apoptosis inducers in chronic lymphocytic leukemia.Idelalisib- a PI3Kδ targeting agent for B-cell malignancies.A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine Biological drugs in Guillain-Barré Syndrome: an update.A Novel Natural Product, KL-21, Inhibits Proliferation and Induces Apoptosis in Chronic Lymphocytic Leukemia Cells.

P2860

Q33438732-8988FD9B-8C97-44BE-A7FD-D8795480B1D9 Q33708995-B80AF048-BB53-4351-8942-8E862F0ED398 Q34324683-A492F8A1-A71F-494B-9897-0310E0D6C0DD Q36771955-893858B7-0721-4CC4-8BEE-8B5BDD1166BE Q36979140-05240C27-E0A8-455B-BC4A-483166E68027 Q38187815-4A785285-C2BD-4DE4-BB0F-E22C8B013105 Q38364936-41E70AE9-5D6D-4D1B-9915-8A69E1A557B2 Q38457498-390E9504-C2EC-4D04-AEB4-CCB3D5FD94E6 Q38783298-F3CC5F78-5709-4368-ACFE-D7977275E261 Q38840067-ACB581D6-1232-413D-933F-C93D4C66EDF0

P2860

Treatment of relapsed or refractory chronic lymphocytic leukemia.

http://www.wikidata.org/entity/Q37964916

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@en

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@nl

type

label

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@en

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@nl

prefLabel

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@en

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@nl

P1433

Q37964916-22B64682-90A7-4885-A305-19C4606AFB4B

P1476

Q37964916-ADE5C672-00C1-4CB2-9008-A878400444D6

P2093

Q37964916-15DB8EB4-6B46-4FE2-BD93-2F4C6A357E40

Q37964916-A485B0E4-C101-455F-B053-F7323C4CC130

P2860

Q37964916-0BD9BEC5-C518-46FC-93CD-9108C5873F66

Q37964916-0C9028A6-E865-4214-BAAA-CD67A79A0BAC

Q37964916-0D19B586-B9A4-4CC9-9C62-C7E8E768C823

Q37964916-0E32061C-1AA8-43A4-AC4F-44AEA68E36D6

Q37964916-0E60E643-587F-4123-9AF6-EC7B905A32BF

Q37964916-0ED142CB-E414-4836-8555-099E0AB88DD2

Q37964916-104273BD-F4B3-4675-AC22-CE88A6A10291

Q37964916-1118F2E0-E0A8-403E-8854-7A1B64E28021

Q37964916-15C3D12C-FAFA-4287-BC25-8D258ACC3D82

Q37964916-1660FA2E-F7B8-41A4-B04E-2298BE390363

P304

Q37964916-640DCD33-55B3-47C8-9BA8-0EB823B157CF

P31

Q37964916-15E6E2FD-1631-41B4-BE71-5C10D6E9D18E

P356

Q37964916-3599A775-FAF0-4F79-8C34-BD96F769E6E9

P433

Q37964916-F51B691C-3778-4D70-9BA9-02D8B7FD2E79

P478

Q37964916-4397FB23-791D-44F5-81CE-20843EF83A36

P577

Q37964916-B7BA6C62-D7C9-4712-BF1B-C703CBF02651

P698

Q37964916-B58637A1-8252-486D-AEF5-D4B6E1204C55

P921

Q37964916-30171342-0452-4826-AA58-41B2691AC938

Q37964916-A6D82656-50C9-4EF0-8BA5-A0F0EB94C71C

P356

107327481201900105

P1433

P1476

Treatment of relapsed or refractory chronic lymphocytic leukemia.

@en

P2093

Javier Pinilla-Ibarz

http://www.w3.org/2001/XMLSchema#string

Marays Veliz

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Genomic aberrations and survival in chronic lymphocytic leukemia

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia.

P304

37-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107327481201900105

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22143061

http://www.w3.org/2001/XMLSchema#string

P921